Rapport Therapeutics' RAP-219 met primary and secondary endpoints in a Phase II bipolar mania trial, cutting YMRS scores. See results and Phase III plans.
Disc Medicine's bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for EPP, setting up an NDA ...
Lilly's Omvoh met its Phase III primary endpoint in pediatric ulcerative colitis, with 50% of responders in remission at Week ...
FDA grants accelerated approval to GSK's Jemperli for stage II/III MSI-H or dMMR locally advanced rectal cancer. Read what this means for patients today.
Gilead's oral α4β7 integrin inhibitor emvistegrast met the primary endpoint in Phase II SWIFT study for ulcerative colitis.
AbbVie (NYSE: ABBV) reported that its investigational dual-targeting combination ABBV-466 achieved primary endpoints in ...
Evaxion's personalized cancer vaccine EVX-01 kept all Phase II melanoma patients in response at three years, with no tumor ...
Entrada's ENTR-601-45 met its Phase I/II safety endpoint at 5 mg/kg in DMD patients, showing modest dystrophin gains. Read ...
Nouscom closes oversubscribed EUR 120M Series D to advance NOUS-209 toward a Lynch syndrome registration trial. Learn what this means for patients.
FDA approves Ryzumvi label expansion for presbyopia, giving Viatris' phentolamine eye drop a second indication. Read the full details and clinical impact.
Betta pan-RAS inhibitor BPI-572270 wins NMPA combination trial acceptance in China, plus Australian and US FDA trial ...
Microbiotica raised USD 48m in its Series C to advance MB310 into a Phase II ulcerative colitis study. Read the complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results